Sanofi-Aventis (SASY.PA), the French drugmaker whose $18.5 billion bid for U.S. biotech Genzyme (GENZ.O) expires on Tuesday, is studying four acquisitions in the ophthalmology sector, Les Echos reported. The acquisitions are worth 1 billion euros ($1.36 billion) overall, the French newspaper reported on Monday. Three of the targets are in the United States and the fourth in Israel, Les Echos said, citing unnamed sources.
Source
